Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: letrozolo+cyclophosphamide|DRUG: letrozolo+sorafenib+cyclophosphamide
Sponsor: University of Turin, Italy